Who Paid My Doc
Laura Davis Keppen
Clinical Genetics (M.D.) Sioux Falls, SD Medical Doctor
NPI 1356394324 CMS profile 242629
1600 W 22Nd St, Sioux Falls, SD 57105
General payments
$20,209
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$9,460
Through program year 2025, Laura Davis Keppen of Sioux Falls, SD is reported in the CMS Open Payments database as having received $20,209 across 42 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $9,460 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 84th percentile of Clinical Genetics (M.D.) profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,297 | 6 | |
| 2024 | General | $2,995 | 2 | |
| 2023 | General | $12,335 | 23 | |
| 2022 | General | $125 | 1 | |
| 2021 | General | $155 | 2 | |
| 2019 | General | $301 | 8 |
Beside peers
- Laura Davis Keppen
- Clinical Genetics (M.D.) median
- Middle half of Clinical Genetics (M.D.)
- National median
In program year 2025, general payments to Laura Davis Keppen were reported at $4,297. Among 315 Clinical Genetics (M.D.) profiles paid that year, the median was $255 and the middle half received between $85 and $3,583.
Show as a table
| Year | Laura Davis Keppen | Clinical Genetics (M.D.) median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $301 | $130 | $24–$2,691 | $163 |
| 2020 | $0 | $126 | $30–$3,700 | $114 |
| 2021 | $155 | $185 | $30–$3,777 | $132 |
| 2022 | $125 | $136 | $44–$2,749 | $149 |
| 2023 | $12,335 | $196 | $55–$5,220 | $160 |
| 2024 | $2,995 | $165 | $46–$3,171 | $164 |
| 2025 | $4,297 | $255 | $85–$3,583 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
63
Drug cost
$843,369
Branded share of claims
36.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Palynziq Pegvaliase-Pqpz | Brand | 12 | $843,022 | |
| Levothyroxine Sodium | Generic | 40 | $268 | |
| Hailey Fe Norethindrone-E.Estradiol-Iron | Brand | 11 | $79 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Records
42 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Genetics (M.D.) in South Dakota
Related records
Clinical Genetics (M.D.) in South Dakota
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Genetics (M.D.)
Everyone recorded under this specialty, nationwide.
Doctors in South Dakota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.